Skip to main content
Top
Published in: Endocrine 1/2009

01-08-2009 | Case Report

Changes of serum and urine neutrophil gelatinase-associated lipocalin in type-2 diabetic patients with nephropathy: one year observational follow-up study

Authors: Yi-Hua Yang, Xiao-Jie He, Shen-Ren Chen, Ling Wang, En-Min Li, Li-Yan Xu

Published in: Endocrine | Issue 1/2009

Login to get access

Abstract

We initiated the present work to explore whether neutrophil gelatinase-associated lipocalin (NGAL) could be used to predict the progression of diabetic nephropathy in type-2 diabetic patients. Seventy-four type-2 diabetic patients were divided into normo-, micro- and macro-albuminuria groups according to their 24 h-urinary albumin excreting rate. Serum and urine NGAL, and other clinical parameters were detected. Patients were followed and measurements were repeated 1 year later. An increased tendency of urine NGAL and a decreased tendency of serum NGAL were detected, from normo-albuminuria group to macro-albuminuria group. Serum NGAL was found to rise after follow-up. Moreover, urine NGAL was found to be correlated positively with cystatin C, urea nitrogen, and serum creatinine (SCr), and inversely with glomerular filtration rate (GFR), while serum NGAL correlated negatively with cystatin C and urea nitrogen, at both baseline and follow-up levels. The results indicate that NGAL correlates closely with renal function. Both serum and urine NGAL are sensitive for predicting the progression of type-2 diabetic nephropathy but they may change differently. Serum NGAL may be more useful in early detection and urine NGAL may be more meaningful in renal function assessment.
Literature
2.
go back to reference A.S. Levey, J. Coresh, E. Balk et al., Ann. Intern. Med. 139, 137–147 (2003)PubMed A.S. Levey, J. Coresh, E. Balk et al., Ann. Intern. Med. 139, 137–147 (2003)PubMed
3.
go back to reference M. Mussap, M. Dalla Vestra, P. Fioretto et al., Kidney Int. 61, 1453–1461 (2000)CrossRef M. Mussap, M. Dalla Vestra, P. Fioretto et al., Kidney Int. 61, 1453–1461 (2000)CrossRef
4.
go back to reference M. Kanauchi, H. Nishioka, T. Hashimoto, K. Dohi, Nippon Jinzo Gakkai Shi 37(11), 649–654 (1995)PubMed M. Kanauchi, H. Nishioka, T. Hashimoto, K. Dohi, Nippon Jinzo Gakkai Shi 37(11), 649–654 (1995)PubMed
5.
go back to reference L. Kjeldsen, A.H. Johnsen, H. Sengelov et al., J. Biol. Chem. 268(14), 10425–10432 (1993)PubMed L. Kjeldsen, A.H. Johnsen, H. Sengelov et al., J. Biol. Chem. 268(14), 10425–10432 (1993)PubMed
8.
go back to reference K. Mori, H.T. Lee, D. Rapoport et al., J. Clin. Invest. 115(3), 610–621 (2005)PubMed K. Mori, H.T. Lee, D. Rapoport et al., J. Clin. Invest. 115(3), 610–621 (2005)PubMed
10.
go back to reference Y.C. Ma, L. Zuo, J.H. Chen et al., J. Am. Soc. Nephro. 17, 2937–2944 (2006)CrossRef Y.C. Ma, L. Zuo, J.H. Chen et al., J. Am. Soc. Nephro. 17, 2937–2944 (2006)CrossRef
15.
18.
go back to reference E. Ishimura, Y. Nishizawa, S. Shoji et al., Life Sci. 58(16), l331–l1337 (1996)CrossRef E. Ishimura, Y. Nishizawa, S. Shoji et al., Life Sci. 58(16), l331–l1337 (1996)CrossRef
19.
20.
go back to reference C. Murray, D. Tammo, M. Bernd et al., J. Mol. Biol. 289(40), 139–157 (1999) C. Murray, D. Tammo, M. Bernd et al., J. Mol. Biol. 289(40), 139–157 (1999)
21.
25.
go back to reference J.R. Bundgaard, H. Sengelov, N. Borregaard, L. Kjeldsen, Biochem. Biophys. Res. Commun. 202(3), 1468–1475 (1994)CrossRefPubMed J.R. Bundgaard, H. Sengelov, N. Borregaard, L. Kjeldsen, Biochem. Biophys. Res. Commun. 202(3), 1468–1475 (1994)CrossRefPubMed
Metadata
Title
Changes of serum and urine neutrophil gelatinase-associated lipocalin in type-2 diabetic patients with nephropathy: one year observational follow-up study
Authors
Yi-Hua Yang
Xiao-Jie He
Shen-Ren Chen
Ling Wang
En-Min Li
Li-Yan Xu
Publication date
01-08-2009
Publisher
Springer US
Published in
Endocrine / Issue 1/2009
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-009-9187-x

Other articles of this Issue 1/2009

Endocrine 1/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine